Oncoinvent ASA (BRRGF)
OTHER OTC:BRRGF
BRRGF Stock Chart & Stats
$0.02
$0.00(0.00%)
At close: 4:00 PM EST
$0.02
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.03 - $0.03
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$20.71M
Enterprise Value-$11.35M
Total Cash (Recent Filing)$140.16M
Total Debt (Recent Filing)$818.00K
Price to Earnings (P/E)―
Beta0.00
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.55
Shares Outstanding4,478,411
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.55
Enterprise Value/Revenue-13.39
Enterprise Value/Gross Profit0.69
Enterprise Value/Ebitda0.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Oncoinvent ASA News
BRRGF FAQ
What was Oncoinvent ASA’s price range in the past 12 months?
Oncoinvent ASA lowest stock price was $0.03 and its highest was $0.03 in the past 12 months.
What is Oncoinvent ASA’s market cap?
Oncoinvent ASA’s market cap is $20.71M.
When is Oncoinvent ASA’s upcoming earnings report date?
Oncoinvent ASA’s upcoming earnings report date is Aug 27, 2026 which is in 71 days.
How were Oncoinvent ASA’s earnings last quarter?
Currently, no data Available
Is Oncoinvent ASA overvalued?
According to Wall Street analysts Oncoinvent ASA’s price is currently Overvalued.
Does Oncoinvent ASA pay dividends?
Oncoinvent ASA does not currently pay dividends.
What is Oncoinvent ASA’s EPS estimate?
Oncoinvent ASA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncoinvent ASA have?
Oncoinvent ASA has 4,478,411 shares outstanding.
What happened to Oncoinvent ASA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oncoinvent ASA?
Currently, no hedge funds are holding shares in BRRGF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncoinvent ASA
Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to developing innovative radiopharmaceutical treatments for various cancers. Its primary therapeutic agent is Radspherin, an alpha-emitting radiotherapeutic, which is currently undergoing investigation in two Phase 1/2a and one randomized Phase 2 clinical trials. This promising candidate is designed to target and treat malignancies that have metastasized to body cavities, specifically including the peritoneum.
Bioxcel Therapeutics
―
Cellectar Biosciences
―
Fennec Pharmaceuticals
―
Geron
―
Kazia Therapeutics
―
Sorrento Therapeutics
―